Our Commitment To Cancer Patients
At Context Therapeutics, we are passionate about improving health and committed to helping people with cancer. To fulfill our promise to patients, we have created the ONWARD Clinical Trial network to evaluate our investigational product, Apristor (onapristone xr) across breast, ovarian, and endometrial cancers.
2L PR+ mBCa
ONWARD 201 will evaluate Apristor in second line (2L) metastatic breast cancer patients who are progesterone receptor positive (PR+) and who have failed prior antiestrogen monotherapy or the combination of an antiestrogen plus a Cdk4/6 inhibitor,
Window of Opportunity
ONWARD 203 will evaluate Apristor in pre-surgical treatment naive breast cancer patients alone and in combination with standard of care agents.
2L Endometrial Cancer
ONWARD 220 will evaluate Apristor in chemotherapy resistant endometrioid adenocarcinoma patients.
Developing the next generation of antihormonal therapies to treat breast, prostate, and ovarian cancers.
Apristor is an investigational New Chemical Entity (NCE) for PR+ breast and ovarian cancers.